AL-ADTRAN
13.3.2023 14:01:39 CET | Business Wire | Press release
Adtran®, Inc., (NASDAQ:ADTN), the leading provider of next-generation open and disaggregated networking solutions, and Satelles, Inc., the leading supplier of secure time and location technology using low-earth orbit (LEO) satellites, today announced a strategic partnership. The collaboration will enable operators of critical infrastructure to safeguard their timing networks with Satellite Time and Location (STL) technology. By integrating Satelles’ STL into its Oscilloquartz network synchronization products, Adtran will provide an alternative to GNSS systems or a way to augment them with enhanced reliability and security. With the ability to deliver highly precise PNT service, even in GNSS-denied applications, STL offers a vital resource for mobile operators, power utility companies, government, scientific research and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005475/en/
Adtran’s partnership with Satelles will further strengthen its aPNT+™ solution. (Photo: Business Wire)
“We’re pleased to be working with Adtran’s Oscilloquartz division to integrate STL into its portfolio of PTP network timing devices. Together, we’re enabling even more customers to benefit from their game-changing aPNT+™ technology,” said Christina Riley, VP and GM of commercial enterprise solutions at Satelles. “Leveraging LEO signals that are 1,000 times stronger than GNSS, our STL solution is transforming the PNT industry. It’s ideal for providing accurate, reliable timing where GNSS can’t reach, such as indoor locations. And in settings where it is possible to receive GNSS signals, STL complements it with additional PNT services to improve resiliency. Easy and affordable to install, STL also offers new levels of security for synchronization network infrastructure.“
STL provides augmented and secure backup for GPS or other GNSS by harnessing encrypted signals transmitted via LEO satellites. It ensures timing and location information that is highly precise, robustly secure, and accessible worldwide. STL is effectively impervious to cyberattacks and is far less susceptible to GNSS vulnerabilities such as signal disruption and manipulation. And because STL signals are up to 1,000 times stronger than GNSS, they can easily reach into buildings and other hard-to-reach locations. Through its partnership with Satelles, Adtran’s Oscilloquartz division will incorporate these benefits into its end-to-end timing toolkit. What’s more, as well as integrating STL into its grandmaster clocks, it will develop miniature M.2 form factor STL receiver modules for third-party product integration.
“We’re excited to offer Satelles’ innovative STL technology as the perfect addition to our portfolio. Reliable, precise and secure, STL is an excellent source of alternative PNT services that’s ideal for use in situations where distributed PTP is unavailable. It also creates new market opportunities for indoor 5G and data center use cases. By incorporating it into our solutions, we’ll empower operators of mission-critical networks to bring robust timing to the most challenging environments and remove the expense of installing outdoor antennas and coring through concrete,” commented Gil Biran, GM of Oscilloquartz, Adtran. “This partnership reinforces our commitment to providing the most advanced and reliable network timing solutions available, and we look forward to bringing the advantages of STL to customers around the world.”
About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. Adtran, Inc. is a wholly-owned subsidiary of ADTRAN Holdings, Inc. (NASDAQ:ADTN and FSE: QH9). Find more at Adtran, LinkedIn and Twitter.
About Satelles
Satelles protects critical infrastructure by providing STL as an alternative positioning, navigation, and timing (PNT) technology that delivers stability, reliability, and trust required by commercial enterprises and government entities. STL’s secure signal from low Earth orbit (LEO) is resilient to regional outages of GPS and other GNSS. Customers turn to Satelles for a primary source of PNT, and STL also safeguards against devastating attacks to GPS/GNSS capable of disrupting or disabling electrical grids, wireless communications networks, financial systems, and other private and public infrastructure. Built on a foundation of expertise in the public sector, Satelles delivers first-to-market proven technology that is sold commercially throughout the world today. Learn more at www.satelles.com.
Published by
Adtran, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005475/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
